A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.
Holmén C, et al. Among authors: svenningsson a.
Mult Scler. 2011 Jun;17(6):708-19. doi: 10.1177/1352458510394701. Epub 2011 Jan 12.
Mult Scler. 2011.
PMID: 21228027